GlaxoSmithKline PLC


  • *Drug has orphan drug status in US, EU and Japan. Aug 20- Amicus Therapeutics Inc moved a step closer to bringing its first drug to the market after trial results paved the way for its lead drug to become the first oral treatment for patients with a disorder that causes an abnormal build-up of fat.

  • Aug 20- Amicus Therapeutics Inc said its experimental drug was as effective as enzyme replacement therapies after 18 months in patients with Fabry disease, an inherited disorder that leads to the abnormal build-up of fat. The company's stock rose 38 percent in premarket trading on Wednesday after the results of the second late-stage trial were released.

  • NORWICH, England, Aug 17- Pampering leafcutter ants with fragrant rose petals and fresh oranges may seem an unlikely way to rescue modern medicine, but scientists at a lab in eastern England think it's well worth trying.

  • Scientists racing to test Ebola vaccines in humans Thursday, 14 Aug 2014 | 5:36 PM ET

    New details about the development of the vaccines emerged this week as the World Health Organization declared it OK to use experimental drugs and vaccines as authorities try to contain the outbreak that has killed more than 1,000 people.

  • NEW YORK, Aug 13- Biotechnology company InterMune Inc is working with financial advisers to evaluate strategic options as it braces for potential takeover interest from larger drugmakers, people familiar with the matter said.

  • Aug 13- BioCryst Pharmaceuticals Inc said the U.S. government exercised options to test the company's antiviral drug in humans and non-primates as a treatment for hemorrhagic fever viruses such as Ebola.

  • *Liberia to treat infected doctors with trial drug ZMapp. LONDON/ GENEVA, Aug 12- People infected in the West African Ebola outbreak can be offered untested drugs, the World Health Organisation said on Tuesday, but the scarcity of supplies has raised questions about who gets priority access to treatment.

  • *Liberia to treat infected doctors with trial drug ZMapp. LONDON/ GENEVA, Aug 12- People infected in the West African Ebola outbreak can be offered untested drugs, the World Health Organisation said on Tuesday, but the scarcity of supplies raises questions about who gets priority access to treatment.

  • LONDON, Aug 12- World Health Organization experts fighting the world's worst outbreak of Ebola hope for improved supplies of experimental treatments and progress with a vaccine by the end of the year.

  • *KKR teams up with Rhone Capital for $3.1 bln takeover offer. HONG KONG, Aug 12- A KKR& Co- led takeover of Australia's Treasury Wine Estates Ltd would likely lead to a long and drastic overhaul, resulting in a much smaller but more profitable company, bankers familiar with the matter said.

  • The Ebola epidemic in West Africa has killed nearly 1,000 people and prompted the World Health Organization to declare an international health emergency. GSK is co-developing a vaccine with the U.S. National Institute of Allergy and Infectious Diseases, which has shown promising results in primates.

  • LONDON, Aug 11- GlaxoSmithKline faces new allegations that it bribed Syrian doctors and officials to boost sales of its medicines, following recent accusations of corruption in its non-prescription business in the country.

  • AIDS activist takes up a new fight: defending FDA Monday, 11 Aug 2014 | 11:34 AM ET

    A quarter century later, Gonsalves still travels to Washington, but with a different agenda: to defend the FDA. The efforts include new state laws designed to undercut the FDA's authority by giving patients early access to unapproved drugs and a lobbying push by industry groups to speed up the time it takes the FDA to review new treatments.

  • Reuters Business News Schedule at 1900 GMT/1500 EDT Sunday, 10 Aug 2014 | 3:00 PM ET

    PRETORIA- South Africa's central bank steps in to rescue unsecured lender African Bank Investments, placing it under external supervision and announcing plans for a $940 million capital injection underwritten by local lenders. Europe's fragile economy put to test as Ukraine, Iraq sour mood.

  • Clinical trial to start soon on GSK Ebola vaccine Sunday, 10 Aug 2014 | 11:33 AM ET

    LONDON, Aug 10- A clinical trial of an experimental vaccine against the deadly Ebola virus is set to start shortly, according to British drugmaker GlaxoSmithKline, which is co-developing the product with U.S. scientists.

  • US labs on standby to start work on Ebola drug Sunday, 10 Aug 2014 | 6:02 AM ET
    A nurse wears protective clothing as he demonstrates the facilities in place at the Royal Free Hospital in north London on August 6, 2014, in preparation for a patient testing positive for the Ebola virus.

    All three U.S. laboratories established to fight major public health threats say they are standing by to scale up a treatment for Ebola.

  • NEW YORK/ WASHINGTON, Aug 9- All three U.S. facilities established to quickly make vaccines and therapeutics in the event of a major public health threat say they are standing by to support any U.S. government effort to scale up a treatment for Ebola.

  • GSK-linked investigator found guilty in China trial Friday, 8 Aug 2014 | 12:12 PM ET
    An internal court video shows British investigator Peter Humphrey arriving at a courtroom after a lunch break, during his trial at Shanghai No.1 Intermediate People's Court August 8, 2014.

    An investigator linked to the U.K. drug giant GSK was convicted in a case that many say highlights the risks of conducting due diligence in China.

  • China jails British-US investigator couple Friday, 8 Aug 2014 | 12:29 AM ET

    Peter Humphrey and Yingzeng Yu, a married couple, operated a firm in Shanghai that helped companies screen potential business partners and employees. 1 Intermediate Court to 2 1/ 2 years in prison to be followed by expulsion from China. Humphrey was also fined 200,000 yuan and Yu 150,000 yuan.

  • NEW YORK, Aug 5- Belgian pharmaceutical company UCB is exploring a sale of its Kremers Urban Pharmaceuticals Inc division, a U.S. specialty generics business that could fetch as much as $2 billion, according to people familiar with the matter. Other companies that are exploring similar sales include GlaxoSmithKline Plc, Sanofi SA and Merck& Co Inc..